Aligos Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 6, 2026, disclosing share counts, warrant positions, and its status as a clinical-stage biotechnology company with no approved products.
Key Highlights
- Shares outstanding: As of November 3, 2026, the registrant had 6,248,478 shares of common stock outstanding.
- Voting vs. non-voting split: Outstanding shares comprised 5,448,478 shares of voting common stock and 800,000 shares of non-voting common stock.
- Pre-funded warrants: An additional 4,217,432 shares of common stock are issuable upon exercise of pre-funded warrants outstanding as of November 3, 2026, sold in private placements on October 23, 2023 and February 13, 2025.
- Warrant exercise prices: The pre-funded warrants are immediately exercisable at exercise prices of $0.0025 and $0.0001 per share, subject to beneficial ownership limitations.
- Filer status: The registrant is classified as a non-accelerated filer and a smaller reporting company.
- No approved products: According to the filing, the company is a clinical-stage biotechnology company with no products approved for commercial sale and has incurred significant losses since inception.
Aligos Therapeutics Share Structure and Clinical Status at September 30, 2026
Aligos Therapeutics, Inc. (NASDAQ:ALGS), headquartered in South San Francisco, California, submitted its quarterly report covering the period ended September 30, 2026. As of November 3, 2026, the company reported 6,248,478 total shares of common stock outstanding, consisting of 5,448,478 shares of voting common stock and 800,000 shares of non-voting common stock, each with a par value of $0.0001 per share, according to the filing.
The filing disclosed that 4,217,432 additional shares of common stock are issuable upon the exercise of pre-funded warrants outstanding as of November 3, 2026. These warrants, which are immediately exercisable at exercise prices of $0.0025 and $0.0001 per share of common stock, were sold in the registrant's private placements conducted on October 23, 2023 and February 13, 2025. The company noted these warrants are subject to beneficial ownership limitations. The filing directed readers to Note 7 - Common Warrants and Pre-Funded Warrants in the unaudited condensed consolidated financial statements for further detail.
The registrant described itself as "a clinical-stage biotechnology company with a limited operating history and no products approved for commercial sale," adding that it "has incurred significant losses since inception" and expects "to incur losses for at least the next several years." The filing contains forward-looking statements that, as the company stated, involve "known and unknown risks, uncertainties and other important factors" and are subject to the cautionary language described in the filing's Risk Factors section. The company is registered under Commission File Number 001-39617 on the Nasdaq Capital Market.
What Was Disclosed
Aligos Therapeutics filed its Form 10-Q for the quarter ended September 30, 2026, reporting 6,248,478 shares of common stock outstanding, 4,217,432 shares underlying pre-funded warrants, and its ongoing status as a clinical-stage company with no approved products and continued operating losses.




Please wait processing your request...